TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

20 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

15 studies on the map

Self-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy — Beth Israel Deaconess Medical Center, BostonEffect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD — Washington DC Veterans Affairs Medical Center (688), Washington D.C.Mechanism of SGLT2 Inhibition in the Kidney — University of Michigan, Ann ArborPharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE) — University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, CincinnatiProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) — Cincinnati Children's Hospital Medical Center, CincinnatiClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression — Laureate Institute for Brain Research, TulsaEmpagliflozin Treatment in Kidney Transplant Recipients — Edward Hines Jr. VA Hospital, Hines, IL, HinesPioglitazone to Reduce Sympathetic Overactivity in CKD Patients — University of Texas at Arlington, ArlingtonOral Iron in Children With Chronic Kidney Disease — Weill Cornell Medicine / New York Presbyterian Hospital, New YorkTrial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders. — University of Cincinnati, CincinnatiAcute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A) — University of Cincinnati, CincinnatiRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamSafety of Short-course of NSAIDs in Pediatric Patients With CKD — Children's Hospital Colorado, Aurora